Rose Conway Walsh (Sinn Fein) | Oireachtas source

Yes, of course. The cost-benefit analysis needs to take account of the alternative medication, the hospitalisation and all other services that will be required by the individual. The very first thing that anyone needs to do is to go to the drug company and negotiate a discount based on the increased volume. That was not done. That does not speak to me as a service that is patient-centred.

I acknowledge this is not the area for which the witnesses are responsible but it is connected to their areas. They should please ask that another look be taken at Versatis medicated plasters. The position should be reviewed and in the meantime, the Versatis patches should be reinstated. It should be left to the GPs and the consultants to make that decision.